Selecta Biosciences, Inc.
(NASDAQ : SELB)

( )
SELB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.23%89.071.3%$885.86m
AMGNAmgen Inc.
0.09%191.491.2%$554.58m
GILDGilead Sciences, Inc.
0.72%65.490.9%$453.28m
ONCESpark Therapeutics, Inc.
-0.25%113.6711.2%$443.24m
BIIBBiogen Inc.
-0.58%323.761.3%$352.26m
REGNRegeneron Pharmaceuticals, Inc.
-0.15%406.992.6%$278.79m
ILMNIllumina, Inc.
1.61%310.703.5%$273.06m
BPTHBio-Path Holdings, Inc.
-9.32%25.20190.1%$257.65m
VRTXVertex Pharmaceuticals Incorporated
-3.05%181.761.9%$239.61m
SRPTSarepta Therapeutics, Inc.
-0.28%126.4715.4%$205.98m
EXASExact Sciences Corporation
-0.85%91.1525.3%$189.71m
ALXNAlexion Pharmaceuticals, Inc.
-0.43%132.942.0%$178.02m
AAgilent Technologies, Inc.
0.28%81.201.6%$151.29m
IONSIonis Pharmaceuticals, Inc.
0.11%79.618.3%$101.25m
BMRNBioMarin Pharmaceutical Inc.
-2.06%91.444.3%$95.59m

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.